Back to Trials
NCT06911931NARecruitingAccepts Healthy Volunteers

Visual Perception in Schizophrenia

University of Rochester

Start Date

11/3/2025

Completion Date

1/31/2027

Summary

This study aims to identify novel markers of psychosis using electroencephalography (EEG).

Eligibility Criteria

Age Range: 18 years to 65 years

Inclusion Criteria: * All Subjects * Aged 18-65 * 20/32 visual acuity or better (using in-house optical correction, if necessary) * An ability to speak English well enough to complete study assessments and to consent to the study * Subjects with Schizophrenia-Spectrum Disorder * Meets DSM-5 diagnostic criteria for schizophrenia, schizoaffective disorder, or schizophreniform disorder as confirmed by the Structured Interview for DSM-5 (SCID-5). * Subjects with Bipolar Disorder * Meets DSM-5 diagnostic criteria for bipolar disorder (type I, II, or unspecified) as confirmed by the Structured Interview for DSM-5 (SCID-5). Exclusion Criteria: * All subjects * Presence of characteristics that could impair one's ability to comprehend the nature of the study, provide informed consent, or understand the assessment questions, including the following: * Subject cannot read and understand the instructions well enough to complete the tasks or cannot provide informed consent. * Intellectual impairment (WRAT-5 score \< 70) (at the discretion of experimenter); * Actively intoxicated, as shown via patient self-report or staff report; * Substance use disorder in the past 3 months; * Subject considered high risk for suicidal acts (i.e., active suicidal ideation as determined by clinical interview OR any suicide attempt in 30 days prior to screening); * Subject violence (involving severe/lethal means or violence occurring in prior 6 months) or extreme agitation. * Being in a current manic state * Head injury with loss of consciousness greater than 10 minutes (at the discretion of the experimenter). * Subject has had electroconvulsive therapy (ECT) in the past 8 weeks; * Diagnosed with a neurological condition (tumor, stroke, brain injury) or neurological disorder, including seizure disorders. Diagnosed with pervasive developmental disorder (phone screen or medical records) * Lazy eye or squint or other known ocular pathology * Healthy Control Subjects * Any lifetime psychotic disorder or history of psychiatric hospitalization (self disclosure); * Daily antidepressant, mood stabilizer or antipsychotic medication use in the last 6 months, or benzodiazepine use during the prior 2 days (self-disclosure); iii. First-degree relative(s) with a schizophrenia spectrum disorder (based on subject self-report) or bipolar disorder. * Case-match Control Non-ill Subjects * Any lifetime psychotic disorder (as assessed by SCID/or SSD); * Recurrent depressive episodes or being in a current depressive episode (as assessed by SCID/or SSD) * Persistent threshold psychotic symptoms * History of psychiatric hospitalization; * Daily antidepressant, mood stabilizer or antipsychotic medication use in the last 6 months, or benzodiazepine use during the prior 2 days * First-degree relative(s) with a schizophrenia spectrum disorder (based on subject self-report) or bipolar disorder. * Bipolar Subjects * Persistent threshold psychotic symptoms

Interventions

OTHER

EEG measure of visual processing

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Schizophrenia DisordersBipolar DisorderSchizo Affective Disorder

Locations

University of Rochester

Rochester, New York 14642

United States